Received Jul 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| IPV | POLIO VIRUS, INACT. (IPOL) | SANOFI PASTEUR | 1 | Y1A212M | OT |
receiving the 2nd dose 7-days too early with no reported adverse event; Initial information received on 24-Jul-2025 (live follow-up processed together) regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 57 years old female patient who received the 2nd dose of IPV (Vero) [Ipol] 7-days too early with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 02-Jul-2025, the patient received 0.5ml dose 1 of suspect IPV (Vero) (once), Strength Standard, lot Y1A212M and expiry date 31-Jan-2027 via unknown route in unknown administration site for immunisation On 23-Jul-2025 she also received second 0.5ml dose 2 of suspect IPV (Vero) (once), Strength Standard, lot Y1A212M and expiry date Jan-2027 via unknown route in unknown administration site for immigration, 7-days early with no reported adverse event (inappropriate schedule of product administration) (latency Same day). Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.